BMT CTN Protocol 1506

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.

Below are protocol-related documents, which may be periodically updated.

  • Protocol, Version 1.0 dated September 23, 2016
  • Key Personnel

             Protocol Co-Chair: Yi-Bin Chen, MD ychen6@partners.org

             Protocol Co-Chair: Mark Levis, MD, PhD levisma@jhmi.edu

             Protocol Officer: Mehdi Hamadani, MD mhamadani@mcw.edu        

             Protocol Coordinator: Heather Wittsack hwittsack@emmes.com

           

The BMT CTN is committed to including widespread transplant community participation in these trials. For information on how to apply to participate on this study, please contact the Protocol Coordinator Heather Wittsack at hwittsack@emmes.com for details.